H. Pylori Treatment in the COVID-19 Era. What Have We Learned So Far?

Q1 Medicine

Current Gastroenterology Reports Pub Date : 2024-03-01 Epub Date: 2024-02-02 DOI:10.1007/s11894-024-00922-y

Konstantinos Ekmektzoglou, Theodore Rokkas

{"title":"H. Pylori Treatment in the COVID-19 Era. What Have We Learned So Far?","authors":"Konstantinos Ekmektzoglou, Theodore Rokkas","doi":"10.1007/s11894-024-00922-y","DOIUrl":null,"url":null,"abstract":"Purpose of review: CoronaVirus Disease of 2019 (COVID-19) has negatively influenced the management of multiple conditions in regards to the gastroenterology patient. An equivalent change in the management of Helicobacter pylori (H. pylori)-related diseases was reported, as practically no eradication treatment was offered during most of the pandemic. Given the scarcity of published data, we performed a literature review trying to elucidate the effect of COVID-19 on H. pylori treatment.Recent findings: COVID-19 has produced more questions than answers as to the outcome of COVID-19 in H. Pylori infected patients, post-COVID-19 patients treated for H. pylori, acid suppression and COVID-19 incidence and outcomes, and H. pylori eradication treatment in patients having recovered from COVID-19. We strongly believe that this scientific uncertainty produced by the COVID-19 pandemic has set up the stage for an incremental change in H. pylori treatment as COVID-19 has offered us the chance to speed up how we will, in the near future, approach patients with a possible Η. pylori infection.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"86-91"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10937748/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Gastroenterology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11894-024-00922-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: CoronaVirus Disease of 2019 (COVID-19) has negatively influenced the management of multiple conditions in regards to the gastroenterology patient. An equivalent change in the management of Helicobacter pylori (H. pylori)-related diseases was reported, as practically no eradication treatment was offered during most of the pandemic. Given the scarcity of published data, we performed a literature review trying to elucidate the effect of COVID-19 on H. pylori treatment.

Recent findings: COVID-19 has produced more questions than answers as to the outcome of COVID-19 in H. Pylori infected patients, post-COVID-19 patients treated for H. pylori, acid suppression and COVID-19 incidence and outcomes, and H. pylori eradication treatment in patients having recovered from COVID-19. We strongly believe that this scientific uncertainty produced by the COVID-19 pandemic has set up the stage for an incremental change in H. pylori treatment as COVID-19 has offered us the chance to speed up how we will, in the near future, approach patients with a possible Η. pylori infection.

查看原文本刊更多论文

H.COVID-19 时代的幽门螺杆菌治疗。我们目前学到了什么？

审查目的：2019 年科罗纳病毒病（COVID-19）对胃肠病患者的多种疾病管理产生了负面影响。据报道，幽门螺杆菌（H. pylori）相关疾病的治疗也发生了同样的变化，因为在大流行期间几乎没有提供根除治疗。鉴于发表的数据很少，我们进行了一次文献综述，试图阐明 COVID-19 对幽门螺杆菌治疗的影响：COVID-19 在幽门螺杆菌感染者中的疗效、COVID-19 后幽门螺杆菌患者的治疗、抑酸和 COVID-19 的发生率和疗效、COVID-19 后患者的幽门螺杆菌根除治疗等方面产生的问题多于答案。我们坚信，COVID-19 大流行所带来的科学不确定性为幽门螺杆菌治疗的渐进式变革奠定了基础，因为 COVID-19 为我们提供了一个机会，让我们在不久的将来加快处理可能感染幽门螺杆菌的患者的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Gastroenterology Reports Medicine-Gastroenterology

CiteScore

7.80

自引率

0.00%

发文量

期刊介绍： As the field of gastroenterology and hepatology rapidly evolves, the wealth of published literature can be overwhelming. The aim of the journal is to help readers stay abreast of such advances by offering authoritative, systematic reviews by leading experts. We accomplish this aim by appointing Section Editors who invite international experts to contribute review articles that highlight recent developments and important papers published in the past year. Major topics in gastroenterology are covered, including pediatric gastroenterology, neuromuscular disorders, infections, nutrition, and inflammatory bowel disease. These reviews provide clear, insightful summaries of expert perspectives relevant to clinical practice. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. We also provide commentaries from well-known figures in the field.